US EditionPhase 1 trial of STX-0712 for rare cancer CMML doses first patient
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Phase 1 trial of STX-0712 for rare cancer CMML doses first patient
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or refractory, meaning hard-to-treat, chronic myelomonocytic leukemia (CMML) and other types of blood cancer. The launch of this first clinical trial was announced by Solu Therapeutics, which is advancing the clinical development of its STX-0712 treatment candidate with $41 million in Series A financing. The …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
